Inflarx NV at JPMorgan Healthcare Conference (Virtual) Transcript
Welcome, everyone, to the 39th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior analysts at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team. Our next presenting company is InflaRx, and speaking on behalf of the company, we have CEO, Niels Riedemann.
(Operator Instructions)
With that, I'll pass it over to Niels. Niels?
Well, thanks so much, Anupam. Much appreciated. Thanks for inviting us to your exciting conference, and I have to give you an update on what's going on with InflaRx. So I'd like to briefly direct you to the cautionary note regarding forward-looking statements since we are a public company. So I'll move through the slide deck and will tell you where I am, so for those of you -- to be able to follow online where we are.
So on Page 3, investment highlights. So we are really focusing on terminal complement inhibition with
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |